Oncimmune Holdings plc
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse ev… Read more
Oncimmune Holdings plc (ONC) - Net Assets
Latest net assets as of August 2024: GBX-2.40 Million GBX
Based on the latest financial reports, Oncimmune Holdings plc (ONC) has net assets worth GBX-2.40 Million GBX as of August 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX4.90 Million) and total liabilities (GBX7.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX-2.40 Million |
| % of Total Assets | -48.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 176.42 |
Oncimmune Holdings plc - Net Assets Trend (2012–2024)
This chart illustrates how Oncimmune Holdings plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncimmune Holdings plc (2012–2024)
The table below shows the annual net assets of Oncimmune Holdings plc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-08-31 | GBX-2.40 Million | -465.14% |
| 2023-08-31 | GBX657.00K | +124.09% |
| 2022-05-31 | GBX-2.73 Million | -152.17% |
| 2021-05-31 | GBX5.23 Million | +2794.33% |
| 2020-05-31 | GBX-194.00K | -102.47% |
| 2019-05-31 | GBX7.87 Million | -42.01% |
| 2018-05-31 | GBX13.56 Million | +171.02% |
| 2017-05-31 | GBX5.00 Million | -48.58% |
| 2016-05-31 | GBX9.73 Million | +354.74% |
| 2015-05-31 | GBX-3.82 Million | -103.41% |
| 2014-05-31 | GBX-1.88 Million | -415.93% |
| 2013-05-31 | GBX-364.00K | -161.80% |
| 2012-05-31 | GBX589.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncimmune Holdings plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1952800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX741.00K | % |
| Other Components | GBX43.65 Million | % |
| Total Equity | GBX-2.40 Million | 100.00% |
Oncimmune Holdings plc Competitors by Market Cap
The table below lists competitors of Oncimmune Holdings plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Euro-Med Laboratories Phils Inc
PSE:EURO
|
$155.13 |
|
Big Gold Inc.
F:H7L
|
$155.20 |
|
Beco Steel Ltd
KAR:BECO
|
$155.27 |
|
CORAZON GOLD
BE:2CG
|
$155.29 |
|
First Al-Noor Modaraba
KAR:FANM
|
$154.99 |
|
RISANAMENTO
MU:RN5
|
$154.79 |
|
Alsons Consolidated Resources Inc
PSE:ACR
|
$154.51 |
|
JLM Couture Inc.
PINK:JLMCQ
|
$154.00 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncimmune Holdings plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 657,000 to -2,399,000, a change of -3,056,000 (-465.1%).
- Net loss of 3,628,000 reduced equity.
- New share issuances of 5,000 increased equity.
- Other comprehensive income increased equity by 223,000.
- Other factors increased equity by 344,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-3.63 Million | -151.23% |
| Share Issuances | GBX5.00K | +0.21% |
| Other Comprehensive Income | GBX223.00K | +9.3% |
| Other Changes | GBX344.00K | +14.34% |
| Total Change | GBX- | -465.14% |
Book Value vs Market Value Analysis
This analysis compares Oncimmune Holdings plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-05-31 | GBX-0.01 | GBX1.14 | x |
| 2014-05-31 | GBX-0.04 | GBX1.14 | x |
| 2015-05-31 | GBX-0.07 | GBX1.14 | x |
| 2016-05-31 | GBX0.27 | GBX1.14 | x |
| 2017-05-31 | GBX0.10 | GBX1.14 | x |
| 2018-05-31 | GBX0.24 | GBX1.14 | x |
| 2019-05-31 | GBX0.13 | GBX1.14 | x |
| 2020-05-31 | GBX0.00 | GBX1.14 | x |
| 2021-05-31 | GBX0.08 | GBX1.14 | x |
| 2022-05-31 | GBX-0.04 | GBX1.14 | x |
| 2023-08-31 | GBX0.01 | GBX1.14 | x |
| 2024-08-31 | GBX-0.03 | GBX1.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncimmune Holdings plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -132.46%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (16.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -196.48% | 0.76x | 0.00x | GBX-2.98 Million |
| 2014 | 0.00% | -133.59% | 0.43x | 0.00x | GBX-1.22 Million |
| 2015 | 0.00% | -149.67% | 0.69x | 0.00x | GBX-1.63 Million |
| 2016 | -86.75% | -1963.26% | 0.04x | 1.15x | GBX-9.42 Million |
| 2017 | -100.38% | -2336.28% | 0.03x | 1.28x | GBX-5.52 Million |
| 2018 | -46.53% | -2629.17% | 0.02x | 1.06x | GBX-7.67 Million |
| 2019 | -101.87% | -4685.38% | 0.02x | 1.20x | GBX-8.80 Million |
| 2020 | 0.00% | -1661.89% | 0.05x | 0.00x | GBX-8.44 Million |
| 2021 | -88.54% | -124.34% | 0.15x | 4.64x | GBX-5.15 Million |
| 2022 | 0.00% | -246.49% | 0.22x | 0.00x | GBX-9.24 Million |
| 2023 | 624.66% | 356.25% | 0.14x | 12.84x | GBX4.04 Million |
| 2024 | 0.00% | -132.46% | 0.56x | 0.00x | GBX-3.39 Million |
Industry Comparison
This section compares Oncimmune Holdings plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,807,025
- Average return on equity (ROE) among peers: -134.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncimmune Holdings plc (ONC) | GBX-2.40 Million | 0.00% | N/A | $155.03 |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $1.10K |